bevacizumab 400 mg-Bevacizumab Biosimilar for Advanced Cancer treatment

Cizumab is a DCGI-approved Bevacizumab Biosimilar Injection used in the treatment of colorectal, rectal, ovarian, kidney, cervical, lung, and brain tumors. Available in bevacizumab 400 mg strength, it supports Colon and Rectum Cancer Treatmentetted and targeted therapy plans. Bevacizumab uses include Ovarian Cancer Treatment, Cervical Cancer Treatment, Kidney Cancer Treatment, and Brain Tumor Treatment. Its mechanism of action involves inhibiting VEGેહ, reducing tumor blood supply and slowing growth. Bevacizumab dose depends on cancer type and patient condition. Common bevacizumab side effects may include hypertension, bleeding, and fatigue. It should be administered under strict medical supervision.